Ježek Z, Szczeniowski M, Paluku KM, Mutombo M. Human monkeypox: clinical features of 282 patients. J Infect Dis. 1987;156:293–8.

Article  PubMed  Google Scholar 

Ghazanfar A. Epidemiology, clinical features, diagnosis and management of monkeypox virus: a clinical review article. Cureus. 2022;14(8):e28598.

Dumbell KR, Archard LC. Comparison of white pock (h) mutants of monkeypox virus with parental monkeypox and with variola-like viruses isolated from animals. Nature 1980;286:5768. Nature Publishing Group; 1980;286:29–32.

Ladnyj ID, Ziegler P, Kima E. A human infection caused by monkeypox virus in Basankusu Territory, Democratic Republic of the Congo. Bull World Health Organ. 1972;46:593.

CAS  PubMed  PubMed Central  Google Scholar 

Nguyen PY, Ajisegiri WS, Costantino V, Chughtai AA, MacIntyre CR. Reemergence of human monkeypox and declining population immunity in the context of urbanization, Nigeria, 2017–2020. Emerg Infect Dis. 2021;27:1007–14.

Article  PubMed  PubMed Central  Google Scholar 

Abaza H, Agadi K, Anand A, Elsaid M. Clinical manifestations of monkeypox. Cham: Springer International Publishing; p. 1–5. https://doi.org/10.1007/5584_2022_747

Grant R, Nguyen LBL, Breban R. Modelling human-to-human transmission of monkeypox. Bull World Health Organ. 2020;98:638.

Article  PubMed  PubMed Central  Google Scholar 

Monkeypox. [cited 2022 Oct 6]. Available from: https://www.who.int/news-room/fact-sheets/detail/monkeypox

• Bunge EM, Hoet B, Chen L, Lienert F, Weidenthaler H, Baer LR, et al. The changing epidemiology of human monkeypox—a potential threat? A systematic review. PLOS Negl Trop Dis. 2022;16:e0010141. Public Library of Science. This systematic review demonstrates the global relevance and escalation of MPXV cases since the 1970s.

Di Giulio DB, Eckburg PB. Human monkeypox: an emerging zoonosis. Lancet Infect Dis. 2004;4:15–25. Lancet Publishing Group.

2022 Outbreak Cases and Data | Monkeypox | Poxvirus | CDC. [cited 2022 Sep 30]. Available from: https://www.cdc.gov/poxvirus/monkeypox/response/2022/index.html

• Saxena SK, Ansari S, Maurya VK, Kumar S, Jain A, Paweska JT, et al. Re- emerging human monkeypox: a major public-health debacle. J Med Virol. 2023;95(1):e27902. This paper shows overview about the epidemiology and transmission pattern of MPXV, in addition to possible preventive measures, diagnostics, and therapeutics.

Cidofovir - AdisInsight [Internet]. [cited 2022 Sep 10]. ; [Released 1994 September 14,  Updated 2021 September 23] Available from: https://adisinsight.springer.com/drugs/800001073

De Clercq E. Cidofovir in the treatment of poxvirus infections. Antiviral Res. 2002;55:1–13.

Article  PubMed  PubMed Central  Google Scholar 

Lea AP, Bryson HM. Cidofovir. Drugs. 1996;52:225–30.

Article  CAS  PubMed  Google Scholar 

Magee WC, Hostetler KY, Evans DH. Mechanism of inhibition of vaccinia virus DNA polymerase by cidofovir diphosphate. Antimicrob Agents Chemother. 2005;49:3153–62.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Cidofovir | C8H14N3O6P - PubChem. [cited 2022 Oct 7]. Available from: https://pubchem.ncbi.nlm.nih.gov/compound/60613

Brincidofovir | C27H52N3O7P - PubChem. [cited 2022 Oct 7]. Available from: https://pubchem.ncbi.nlm.nih.gov/compound/483477

Tecovirimat | C19H15F3N2O3 - PubChem. [cited 2022 Oct 7]. Available from: https://pubchem.ncbi.nlm.nih.gov/compound/16124688

Andrei G, Snoeck R. Cidofovir activity against poxvirus infections. Viruses. Multidisciplinary Digital Publishing Institute (MDPI). 2010;2:2803–2830 [Internet]. Available from: https://www.mdpi.com/1999-4915/2/12/2803. Accessed 13 Nov 2022

Siegrist EA, Sassine J. Antivirals with activity against monkeypox: a clinically oriented review. Clinical Infectious Diseases. 2023;76(1):155–64.

Article  CAS  PubMed  Google Scholar 

Cidofovir 75 mg/ml Concentrate for Solution for Infusion - Summary of Product Characteristics (SmPC) - (emc). [cited 2022 Nov 13]. Available from: https://www.medicines.org.uk/emc/product/11151/smpc#gref

Cidofovir. Available from: https://globalrph.com/renal/cidofovir/

Yu J, Raj SM. Efficacy of three key antiviral drugs used to treat orthopoxvirus infections: a systematic review. Glob Biosecurity. 2019;1:28. University of New South Wales.

Quenelle DC, Collins DJ, Kern ER. Efficacy of multiple- or single-dose cidofovir against vaccinia and cowpox virus infections in mice. Antimicrob Agents Chemother. 2003;47:3275. American Society for Microbiology (ASM).

Neyts J, Leyssen P, Verbeken E, De Clercq E. Efficacy of cidofovir in a murine model of disseminated progressive vaccinia. Antimicrob Agents Chemother. 2004;48:2267. American Society for Microbiology (ASM).

Meadows KP, Tyring SK, Pavia AT, Rallis TM. Resolution of recalcitrant molluscum contagiosum virus lesions in human immunodeficiency virus-infected patients treated with cidofovir. Arch Dermatol. 1997;133:987–90. American Medical Association.

Becker C. Schlusswort. Deut Arzteblatt. 2009;106:624.

Google Scholar 

Graef S, Kurth A, Auw-Haedrich C, Plange N, Kern WV, Nitsche A, et al. Clinicopathological findings in persistent corneal cowpox infection. JAMA Ophthalmol. 2013;131:1089–91.

Article  PubMed  Google Scholar 

Toro JR, Wood LV, Patel NK, Turner ML. Topical cidofovir: a novel treatment for recalcitrant molluscum contagiosum in children infected with human immunodeficiency virus 1. Arch Dermatol. 2000;136:983–5.

Article  CAS  PubMed  Google Scholar 

Geerinck K, Lukito G, Snoeck R, De Vos R, De Clercq E, Vanrenterghem Y, et al. A case of human orf in an immunocompromised patient treated successfully with cidofovir cream. J Med Virol. 2001;64:543–9.

Article  CAS  PubMed  Google Scholar 

Calista D. Resolution of recalcitrant human papillomavirus gingival infection with topical cidofovir. Oral Surg, Oral Med, Oral Pathol, Oral Radiol, Endod. 2000;90(6):713–5. Mosby Inc.

Davies EG, Thrasher A, Lacey K, Harper J. Topical cidofovir for severe molluscum contagiosum. Lancet. 1999;353(9169):2042. Elsevier B.V.

Quintana-Castanedo L, Tarín-Vicente EJ, Chiloeches-Fernández C, Sendagorta-Cudós E, Herranz-Pinto P. Recalcitrant molluscum contagiosum successfully treated with intralesional cidofovir in a patient with HIV/AIDS. Int J Dermatol. 2021;60:372–5.

Article  PubMed  Google Scholar 

Raccagni AR, Candela C, Bruzzesi E, Mileto D, Canetti D, Rizzo A, et al. Real-life use of cidofovir for the treatment of severe monkeypox cases. J Med Virol. 2023;95(1):e28218. John Wiley & Sons, Ltd.

Mondi A, Gagliardini R, Mazzotta V, Vita S, Carletti F, Pinnetti C, et al. Clinical experience with use of oral tecovirimat or intravenous cidofovir for the treatment of monkeypox in an Italian reference hospital. J Infect. 2022;0. Elsevier.

Fabrizio C, Bruno G, Cristiano L, Buccoliero GB. Cidofovir for treating complicated monkeypox in a man with acquired immune deficiency syndrome. Infection. 2023;51(2):519–22.

Article  PubMed  Google Scholar 

Cundy KC, Li ZH, Lee WA. Effect of probenecid on the distribution, metabolism, and excretion of cidofovir in rabbits. Drug Metab Dispos. 1996;24.

Wei H, Huang D, Fortman J, Wang R, Shao L, Chen ZW. Coadministration of cidofovir and smallpox vaccine reduced vaccination side effects but interfered with vaccine-elicited immune responses and immunity to monkeypox. J Virol. 2009;83(2):1115–25.

Article  CAS  PubMed  Google Scholar 

Ajmera KM, Goyal L, Pandit T, Pandit R. Monkeypox – anemerging pandemic. IDCases. 2022;29:e01587. Elsevier Ltd.

fda, cder. HIGHLIGHTS OF PRESCRIBING INFORMATION. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/761178s000lbl.pdf

Animal Rule Approvals | FDA. [cited 2022 Sep 11]. Available from: https://www.fda.gov/drugs/nda-and-bla-approvals/animal-rule-approvals

Fanunza E, Frau A, Corona A, Tramontano E. Antiviral Agents against Ebola virus infection: repositioning old drugs and finding novel small molecules. Ann Rep Med Chem. 2018;51:135–73. Academic Press Inc.

Hostetler KY. Alkoxyalkyl prodrugs of acyclic nucleoside phosphonates enhance oral antiviral activity and reduce toxicity: current state of the art. Antiviral Res. 2009;82.

Aldern KA, Ciesla SL, Winegarden KL, Hostetler KY. Increased antiviral activity of 1-O-hexadecyloxypropyl-[2-(14)C]cidofovir in MRC-5 human lung fibroblasts is explained by unique cellular uptake and metabolism. Mol Pharmacol. 2003;63:678–81.

Article  CAS  PubMed  Google Scholar 

Painter W, Robertson A, Trost LC, Godkin S, Lampert B, Painter G. First pharmacokinetic and safety study in humans of the novel lipid antiviral conjugate CMX001, a broad-spectrum oral drug active against double-stranded DNA viruses. Antimicrob Agents Chemother. 2012;56:2726–34.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ciesla SL, Trahan J, Wan WB, Beadle JR, Aldern KA, Painter GR, et al. Esterification of cidofovir with alkoxyalkanols increases oral bioavailability and diminishes drug accumulation in kidney. Antiviral Res. 2003;59:163–71. Elsevier.

Tippin TK, Morrison ME, Brundage TM, Momméja-Marin H. Brincidofovir is not a substrate for the human organic anion transporter 1: a mechanistic explanation for the lack of nephrotoxicity observed in clinical studies. Ther Drug Monit. 2016;38:777–86. Lippincott Williams and Wilkins.

Parker S, Touchette E, Oberle C, Almond M, Robertson A, Trost LC, et al. Efficacy of therapeutic intervention with an oral ether-lipid analogue of cidofovir (CMX001) in a lethal mousepox model. Antiviral Res. 2008;77(1):39–49.

Article  CAS  PubMed  Google Scholar 

Trost LC, Rose ML, Khouri J, Keilholz L, Long J, Godin SJ, et al. The efficacy and pharmacokinetics of brincidofovir for the treatment of lethal rabbitpox virus infection: a model of smallpox disease. Antiviral Res. 2015;117:115–21. Elsevier.

Grossi IM, Foster SA, Gainey MR, Krile RT, Dunn JA, Brundage T, et al. Efficacy of delayed brincidofovir treatment against a lethal rabbitpox virus challenge in New Zealand White rabbits. Antiviral Res. 2017;143:278–86. Elsevier B.V.

Hutson CL, Kondas A V., Mauldin MR, Doty JB, Grossi IM, Morgan CN, et al. Pharmacokinetics and efficacy of a potential smallpox therapeutic, brincidofovir, in a lethal monkeypox virus animal model. mSphere. 2021;6.

Lederman ER, Davidson W, Groff HL, Smith SK, Warkentien T, Li Y, et al. Progressive vaccinia: case description and laboratory-guided therapy with vaccinia immune globulin, ST-246, and CMX001. The Journal of infectious diseases. J Infect Dis; 2012;206:1372–85.

Gazzani P, Gach JE, Colmenero I, Martin J, Morton H, Brown K, et al. Fatal disseminated cowpox virus infection in an adolescent renal transplant recipient. Pediatric nephrology (Berlin, Germany). Pediatr Nephrol; 2017;32:533–6.

Marty FM, Winston DJ, Rowley SD, Vance E, Papanicolaou GA, Mullane KM, et al. CMX001 to prevent cytomegalovirus disease in hematopoietic-cell transplantation. The New England journal of medicine. N Engl J Med; 2013;369:1227–36.

Marty FM, Winston DJ, Chemaly RF, Mullane KM, Shore TB, Papanicolaou GA, et al. A randomized, double-blind, placebo-controlled phase 3 trial of oral brincidofovir for cytomegalovirus prophylaxis in allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2019;25:369–81.

Article  CAS  PubMed  Google Scholar 

Grimley MS, Chemaly RF, Englund JA, Kurtzberg J, Chittick G, Brundage TM, et al. Brincidofovir for asymptomatic adenovirus viremia in pediatric and adult allogeneic hematopoietic cell transplant recipients: a randomized placebo-controlled phase II trial. Biol Blood Marrow Transplant. 2017;23:512–21.

Article  CAS  PubMed  Google Scholar 

El-Haddad D, El Chaer F, Vanichanan J, Shah DP, Ariza-Heredia EJ, Mulanovich VE, et al. Brincidofovir (CMX-001) for refractory and resistant CMV and HSV infections in immunocompromised cancer patients: a single-center experience. Antiviral Res. 2016;134:58–62.

Article  CAS  PubMed  Google Scholar 

Lee YJ, Neofytos D, Kim SJ, Cheteyan L, Huang YT, Papadopoulos EB, et al. Efficacy of Brincidofovir as prophylaxis against HSV and VZV in hematopoietic cell transplant recipients. Transplant Infect Dis. 2018;20:e12977. NIH Public Access.

Adler H, Gould S, Hine P, Snell LB, Wong W, Houlihan CF, et al. Clinical features and management of human monkeypox: a retrospective observational study in the UK. Lancet Infect Dis. 2022;22(8):1153–62.

Article  PubMed  PubMed Central  Google Scholar 

A phase 2a study of IV BCV in subjects with adenovirus infection (ATHENA) - Full Text View - ClinicalTrials.gov. [cited 2022 Sep 11]. Available from: https://www.clinicaltrials.gov/ct2/show/NCT04706923

Chittick G, Morrison M, Brundage T, Nichols WG. Short-term clinical safety profile of brincidofovir: a favorable benefit–risk proposition in the treatment of smallpox. Antiviral Res. 2017;143:269–77. Elsevier B.V.

Kennedy RB, Lane JM, Henderson DA, Poland GA. 54 - Smallpox and Vaccinia. In: Plotkin SA, Orenstein WA, Offit PA, Edwards KM, editors. Plotkin’s Vaccines (Seventh Edition) [Internet]. Elsevier; 2018 [cited 2023 Aug 29]. p. 1001–1030.e12. Available from: https://www.sciencedirect.com/science/article/pii/B9780323357616000547

Rizk JG, Lippi G, Henry BM, Forthal DN, Rizk Y. Prevention and treatment of monkeypox. Drugs Drugs. 2022;82(9):957–63.

Article  CAS  PubMed  Google Scholar 

Hoy SM. Tecovirimat: First global approval. Drugs. 2018;78(13):1377–82. Springer International Publishing.

Creating Value in the $7 Billion Health Security Market SIGA VALUE PROPOSITION Growing Public-Private Markets Critical Need Favorable Policy and Regulatory Environment Proven Track Record. SIGA-Brochure.pdf [Internet]. [cited 2023 Aug 26]. Available from: https://www.siga.com/wp-content/uploads/2019/04/SIGA-Brochure.pdf

CDC. Obtain informed consent prior to tecovirimat initiation. Expanded access IND Protocol: Use of Tecovirimat (TPOXX ®) for treatment of human non-variola orthopoxvirus infections in adults and children. 2022. Available from: https://www.cdc.gov/poxvirus/mpox/clinicians/obtaining-tecovirimat.html

Flora SJS, Pachauri V. Handbook on biological warfare preparedness - 1st Edition [Internet]. [cited 2023 Aug 26]. Available from: https://shop.elsevier.com/books/handbook-on-biological-warfare-preparedness/flora/978-0-12-812026-2

fda, cder. Highlights of prescribing information these highlights do not include all the information needed to use TPOXX ® safely and effectively. See full prescribing information for TPOXX. TPOXX (tecovirimat) capsules, for oral use TPOXX (tecovirimat) injection, for intravenous use. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/214460s000,214461s000lbl.pdf

Tecovirimat - an overview | ScienceDirect Topics. [cited 2022 Nov 26]. Available from: https://www.sciencedirect.com/topics/pharmacology-toxicology-and-pharmaceutical-science/tecovirimat

Mucker EM, Goff AJ, Shamblin JD, Grosenbach DW, Damon IK, Mehal JM, et al. Efficacy of tecovirimat (ST-246) in nonhuman primates infected with variola virus (smallpox). Antimicrob Agents Chemother. 2013;57:6246–53.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Chan-Tack KM, Harrington PR, Choi SY, Myers L, O’Rear J, Seo S, et al.